Authors
Latest:
Dr. Naidoo Discusses Biomarker Testing for Checkpoint InhibitorsJarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.
Latest:
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerJasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.
Latest:
Camidge and Datta Detail the Career of an “Opportunistic Nomad”Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.
Latest:
Dr. Singh on Dose Dense ACTHP in HER2+ Breast CancerJasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.
Latest:
The Loss of My FriendEvery medical specialty is a unique subject, and oncology is no exception. Despite the vastness and depth that it entails, it resorts to some of the most universal laws of “being human.”
Latest:
Dr. Zain on Targets Under Investigation in T-Cell LymphomasJasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.
Latest:
Dr. Rassiwala on Results of "All-comers" Downstaging ProtocolJasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.
Latest:
Challenges With CAR T-Cell Therapies in T-Cell LymphomasJasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.
Latest:
Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian CancerJason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.
Latest:
A Collaborative Model for Advanced Practice Providers Empowers SuccessThe burden on oncologists is becoming unmanageable, leading many practices to turn to advanced practice providers.
Latest:
Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCCMark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.
Latest:
Trastuzumab/Pertuzumab May Be an Effective Chemo-Free Regimen in HR+/HER2+ Breast CancerDual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.
Latest:
Dr. Wright on Measuring Progression and Recurrence in Ovarian CancerJason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.
Latest:
Early-Stage NSCLC Is Ripe for ChangeFollowing a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.
Latest:
Dr Efstathiou on the Evolution of Trimodal Therapy in MIBCJason Efstathiou, MD, DPhil, discusses the utility of trimodal therapy in patients with muscle-invasive bladder cancer.
Latest:
Life Persists: One Fellow Finds Hope Amid Cancer's DestructionIt was midnight and I had just been jarred out of a sound sleep by the startlingly repetitive beeping of my pager.
Latest:
Adding Patient-Specific Comorbidities May Improve Risk Evaluation in MyelofibrosisAdding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.
Latest:
Dr Luke on Results of KEYNOTE-716 of Adjuvant Pembrolizumab in Stage IIB/C MelanomaJason Luke, MD, FACP, discusses the final analysis of distant metastasis–free survival in the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma.
Latest:
Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk MelanomaJason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.
Latest:
Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and LustbergOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
Latest:
KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCCCirculating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.
Latest:
Dr. Long on Surgical Advances in NSCLCJason M. Long, MD, assistant professor of surgery, Division of Cardiothoracic Surgery, University of North Carolina at Chapel Hill, discusses specific minimally invasive thoracic surgery approaches in lung cancer.
Latest:
Dr. Wallen on Surgery in Patients With Advanced Lung CancerJason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.
Latest:
Jason Matney on Deep Inspiration Breath Hold During Radiation Therapy for Breast CancerJason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.
Latest:
Dr. Valent on Ongoing Research With Immunotherapy in Multiple MyelomaJason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.
